Amy L. Dunn, MD :: Nationwide Children's Hospital, Columbus, Ohio

Contact Information

Hematology & Oncology
700 Children's Dr
Columbus, OH 43205 [ map ]
PH: (614) 722-3550
FX: (614) 722-3369

Location Information for Patients

Main Campus

Biography

Dr Dunn received her medical degree from Wright State University School of Medicine in Dayton, Ohio and completed her pediatric and pediatric hematology/oncology training at Emory University in Atlanta, Georgia. She is an Associate Professor of Pediatrics at Nationwide Children's Hospital/Ohio State University where she is the Director of Pediatric Hematology and directs the Hemophilia Treatment Center. She is a member of various professional associations including the American Society of Hematology, World Federation of Hemophilia, The International Society of Thrombosis and Hemostasis, the International Pediatric Hemophilia Network, the International Prophylaxis Study Group and the Hemophilia and Thrombosis Research Society (HTRS). Dr Dunn has served as a reviewer for hematologic journals including the Journal of Pediatric Blood and Cancer, the Journal of Thrombosis and Hemostasis, Blood and Haemophilia. She has published numerous peer-reviewed articles, abstracts, and textbook chapters. In addition, she has given many presentations at national and international medical conferences and has received awards that include US News and World Report Top Doctors and the Atlanta Business Chronicle Healthcare Hero for Healthcare Innovation.

View CV »

Gender:

  • Female

Languages Spoken:

  • English

Education and Training

Medical School

  • Wright State University School of Medicine
    Date Completed: 05/31/1994

Residency

  • Emory University/Children's Healthcare of Atlanta
    Date Completed: 06/30/1997

Fellowship

  • Emory University/Children's Healthcare of Atlanta
    Date Completed: 06/30/2000

Department:

  • Pediatrics

Section:

  • Hematology & Oncology

Specialty:

  • Pediatric Hematology Oncology
  • Pediatrics

Date of Appointment at Nationwide Children’s Hospital:

  • 01/24/2014

Publications

  • Boylan B, Anne S. Rice AS, Dunn AL,Tarantino M, Brettler DB, Barrett JC, Miller CH, and the Hemophilia Inhibitor Research Study Investigators. 2015. Characterization of the Anti-Factor VIII Immunoglobulin Profile in Patients With Hemophilia A Using a Fluorescence-Based Immunoassay.  J Throm Haemostas. Vol. 13, no. 1. (January): 47-53.
  • Flood,Veronica,H; Friedman,Kenneth,D; Gill,Joan,Cox; Haberichter,Sandra,L; Christopherson,Pamela,A; Branchford,Brian,R; Hoffmann,Raymond,G; Abshire,Thomas,C; Dunn,Amy,L; Di Paola,Jorge,A; Hoots,W,Keith; Brown,Deborah,L; Leissinger,Cindy; Lusher,Jeanne,M; Ragni,Margaret,V; Shapiro,Amy,D; Montgomery,Robert,R. 2013. No increase in bleeding identified in type 1 VWD subjects with D1472H sequence variation.  BLOOD. Vol. 121, no. 18. (May): 3742-3744.
  • Miller CM, Rice AS, Boylan B, Shapiro AD, Lentz SR, Wicklund BM, Kelly FM, Soucie JM, and the Hemophilia Inhibitor Research Study Investigators. 2013. Comparison of Clot-based, Chromogenic, and Fluorescence Assays for Measurement of Factor VIII Inhibitors in the U.S. Hemophilia Inhibitor Research Study.  J Throm Haemostas. Vol. 11, no. January: 1300-1309.
  • Lundin, B, Manco-Johnson, M; Ignas, D, Moineddin, R, Blanchette, V, Dunn, A; Gibikote, S; Keshava, S; Ljung, R, Manco-Johnson, M. 2012. An MRI Scale for Assessment of Haemophilic Arthropathy from the International Prophylaxis Study Group.  Haemophilia. Vol. 8, no. 6. (November): 962-970.
  • Dunn, A, Meeks, S, Crawford, C. 2012. Medical Radiation Exposure in Children with Bleeding Disorders: An Institutional Experience.  Haemophilia. Vol. 18, no. 6. (November): 888-891.
  • Balakrishnan, V. Dunn, AL. 2012. A Case of Pigmented Villonodular Synovitis in Conjunction with a Platelet Release Defect in a Pediatric Patient.  Haemophilia. Vol. 19, no. 2. (March): e89-90.
  • Ogawa S, Szlam F, Bolliger D, Ohnishi T, Hosokawa K, Dunn A, Tanaka K. 2012. Evaluation of a Novel Flow Chamber System to Assess Clot Formation in Factor VIII-Deficient Mouse and Anti-factor IXa-treated Human Blood.  Haemophilia. Vol. 18, no. 6. (January): 926-932.
  • Meeks, SL, Chapman R, Kempton CL, Dunn AL. 2012. Late Immune Tolerance Induction in Haemophilia A Patients. Haemophilia- May.  Haemophilia. Vol. 19, no. 3. (January): 445-448.
  • Dunn AL, Austin H, Soucie JM. 2012. Prevalence of Malignancies Among U.S. Male Patients with Haemophilia: A Review of the Haemophilia Surveillance System.  Haemophilia. Vol. 18, no. 4. (January): 532-539.
  • Dunn AL. 2011. Pathophysiology, Diagnosis, and Prevention of Arthropathy in Patients with Hemophilia.  Haemophilia. Vol. 17, no. 4. (January): 571-578.
  • Dunn AL. 2010. Malignancy in Patients with Hemophilia: A Review of the Literature.  Haemophilia. Vol. 16, no. 3. (January): 427-436.
  • Dunn AL., Cox Gill J. 2010. Adenotonsillectomy in Patients with Desmopressin Responsive Mild Bleeding Disorders: A Review of the Literature.  Haemophilia. Vol. 16, no. 5. (January): 427-436.
  • Miller W, Dunn AL, Chiang KY. 2009. Sustained Engraftment and Resolution of Bleeding Phenotype Following Unrelated Cord Blood Hematopoietic Stem Cell Transplantation for Severe Glanzmann Thrombasthenia.  J Ped Hematol Oncol. Vol. 16, no. 5. (January): 711-716.
  • Dunn,Amy,L; Abshire,Thomas,C. 2008. Recombinant tissue plasminogen activator may reduce frequency of central venous access device infection in hemophilia patients undergoing immune tolerance therapy.  PEDIATRIC BLOOD & CANCER. Vol. 50, no. 3. (March): 627-629.
  • Doria AS, Lundin B, Miller S, Kilcoyne RF (in memoriam), Thomas S, Dunn A, Rivard GE, Babyn PS. 2008. Reliability and Construct Validity of the Compatible MRI Scoring System for Evaluation of Haemophilic Elbows in Children.  Haemophilia. Vol. 14, no. 2. (January): 303-314.
  • Dunn AL. 2008. Necrotizing Enterocolitits as a Result of Post-Circumcision Bleeding in a Neonate with Haemophilia A.  Haemophilia. Vol. 14, no. January: 1115-1116.
  • Dunn AL, Abshire TC. 2007. Recombinant Tissue Plasminogen Activator may Reduce Frequency of Central Venous Access Device Infection in Hemophilia Patients Undergoing Immune Tolerance Therapy.  Ped Blood Cancer. Vol. 50, no. 3. (January): 627-629.
  • Dunn,A,L; Abshire,T,C. 2006. Current issues in prophylactic therapy for persons with hemophilia.  ACTA HAEMATOLOGICA. Vol. 115, no. 3-4. (January): 162-171.
  • Dunn,A,L; Abshire,T,C. 2005. Recent advances in the management of the child who has hemophilia.  HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA. Vol. 18, no. 6. (December): 1249-1276.
  • Dunn AL, Busch MT, Wyly BJ, Sullivan KM, Abshire TC. 2004. Arthroscopic Synovectomy for Hemophilic Joint Disease in a Pediatric Population.  J of Ped Orthop. Vol. 24, no. 4. (July): 414-426.
  • Dunn AL, Busch MT, Wyly BJ, Sullivan KM, Abshire TC. 2004. Arthroscopic Synovectomy for Hemophilic Joint Disease in a Pediatric Population.  J of Ped Orthop. Vol. 24, no. 4. (January): 414-426.
  • Dunn AL, Busch MT, Abshire TC. 2002. Radionuclide Synovectomy for Hemophilic Arthropathy: a Comprehensive Review of Safety and Efficacy and Recommendation for a Standardized Treatment Protocol.  Thrombos and Haemostas. Vol. 87, no. 3. (March): 383-393.
  • 1. Dunn AL, Powers JR, Ribeiro MJ, Rickles FR, Abshire TC. 2000. Adverse Events During use of Intranasal Desmopressin Acetate for Haemophilia A and von Willebrand Disease: a Case Report and Review of Forty Patients.  Haemophilia. Vol. 6, no. January: 611-614.
  • Dunn AL, Powers JR, Ribeiro MJ, Rickles FR, Abshire TC. 2000. Adverse Event During use of Intranasal Desmopressin Acetate for Haemophilia A and von Willebrand Disease: a Case Report and Review of Forty Patients.  Haemophilia. Vol. 6, no. 6. (January): 611-614.
  • Dunn AL, Busch MT, Abshire TC. Radionuclide Synovectomy for Hemophilic Arthropathy: a Comprehensive Review of Safety and Efficacy and Recommendation for a Standardized Treatment Protocol.  Thrombos and Haemostas.
  • Boylan B, Rice AS, De Staercke C, Eyster EM, Yaish HM, Knoll CM, Bean CJ, Miller CH, and the Hemophilia Inhibitor Research Study Investigators. Evaluation of VWF phenotypes and genotypes in Hemophilia A patients with and without identified F8 mutations.  J Throm Haemostas.

NEXT Consortium

Now children everywhere can have faster access to our discoveries and the most advanced blood disorder and cancer treatments possible.

Learn More About the NEXT Consortium »

Nationwide Children's Hospital
700 Children's Drive Columbus, Ohio 43205 614.722.2000